Affiliations
- PMID: 33980556
- PMCID: PMC8118027
- DOI: 10.1136/bcr-2021-241634
Abstract
A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis.
Keywords: GI bleeding; haematology (drugs and medicines); transplantation.
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.